Department of Neurological Surgery, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan.
J Neurooncol. 2010 Nov;100(2):225-32. doi: 10.1007/s11060-010-0182-0.
The purpose of this retrospective study was to evaluate the prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in immunocompetent patients with primary central nervous system lymphoma (PCNSL). We also investigated whether FDG uptake was related to angiogenesis in the tumors. Seventeen patients with newly diagnosed and histologically confirmed PCNSL were investigated with FDG-PET before the treatment. FDG uptake was assessed by standardized uptake value of the tumor showing the maximum uptake (SUVmax). The Kaplan–Meier method was used to estimate the overall and the progression-free survival times. The difference of the survival curves between the low to moderate FDG uptake (SUVmax < 12) and high FDG uptake (SUVmax ≥ 12) groups was statistically analyzed. The relationship between FDG SUVmax and microvessel density (MVD) in the tumor specimens determined by CD34 immunohistochemical staining was examined. Finally, the difference of the overall survival curve between the low MVD (<20) and high MVD (≥ 20) groups was statistically analyzed. After the completion of initial treatment, 7 of the 8 low to moderate FDG uptake patients showed complete response (CR) and 1 showed partial response (PR). On the other hand, 5 of the 9 high FDG uptake patients showed CR and 4 showed PR. However, the difference of treatment response (CR vs PR) between the low to moderate and high FDG uptake groups was not statistically significant (P = 0.36). Median survival time was more than 26 months in low to moderate FDG uptake patients and 12 months in high FDG uptake patients. The overall survival time of patients with low to moderate FDG uptake was significantly longer than that of patients with high FDG uptake (P < 0.05). The progression free survival (PFS) was also significantly longer in patients with low to moderate FDG uptake compared to the patients with high FDG uptake (P < 0.05). There was no significant relationship between FDG SUVmax and MVD in the tumors. The survival time tended to be longer in patients with high MVD than in low MVD, but the difference was not statistically significant (P = 0.15). Pretreatment FDG uptake may have a prognostic value in newly diagnosed PCNSL.
这项回顾性研究的目的是评估 18F-氟脱氧葡萄糖(FDG)正电子发射断层扫描(PET)在原发性中枢神经系统淋巴瘤(PCNSL)免疫功能正常患者中的预后价值。我们还研究了 FDG 摄取是否与肿瘤中的血管生成有关。17 例新诊断和组织学证实的 PCNSL 患者在治疗前接受 FDG-PET 检查。通过显示最大摄取的肿瘤的标准化摄取值(SUVmax)评估 FDG 摄取。使用 Kaplan-Meier 方法估计总生存期和无进展生存期。统计学分析 SUVmax 低至中等(SUVmax <12)和 FDG 摄取高(SUVmax ≥12)组之间的生存曲线差异。检查肿瘤标本中 CD34 免疫组化染色确定的 FDG SUVmax 与微血管密度(MVD)之间的关系。最后,统计学分析总生存曲线中 MVD 低(<20)和高(≥20)组之间的差异。初始治疗完成后,8 例 SUVmax 低至中等的患者中有 7 例完全缓解(CR),1 例部分缓解(PR)。另一方面,9 例 SUVmax 高的患者中有 5 例 CR 和 4 例 PR。然而,SUVmax 低至中等和高 FDG 摄取组之间的治疗反应(CR 与 PR)差异无统计学意义(P = 0.36)。SUVmax 低至中等的患者中位生存时间超过 26 个月,SUVmax 高的患者为 12 个月。SUVmax 低至中等的患者总生存时间明显长于 SUVmax 高的患者(P <0.05)。SUVmax 低至中等的患者无进展生存期也明显长于 SUVmax 高的患者(P <0.05)。肿瘤中 FDG SUVmax 与 MVD 之间无显著相关性。MVD 高的患者生存时间有延长趋势,但差异无统计学意义(P = 0.15)。治疗前 FDG 摄取可能对新诊断的 PCNSL 具有预后价值。